India’s Alembic Pharma opens anticancer manufacturing plant in Gujarat

Alembic Pharmaceuticals opens oncology manufacturing facility in India.

API drugmaker Alembic Pharmaceuticals is diving into the oncology arena by opening an anticancer manufacturing facility at Panelav, Halol, in Gujarat.

The company, best known for manufacturing anti-infective, analgesic and cough and cold therapies, said the facility will manufacture 60 million tablets and capsules and about 20 million vials of liquid injectable and lyophilized concentrates.

Chirayu Amin, chairman of Alembic, said the company expects to export oncology products to the U.S., Middle East, North Africa, Australia and South Africa. The facility boasts the latest manufacturing equipment from Germany, Belgium, the U.K., and China, he said.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Alembic managing director Pranav Amin said the company is looking to invest about $23 million as part of its expansion plan over the next three years, the Economic Times Healthworld reported.

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.